primary endpoint

Type: Keyphrase
Name: primary endpoint
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Boston Scientific Corporation announces primary endpoint results of NECTAR-HF clinical trial

:39pm EDTBoston Scientific Corporation:Says that it has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial.Says the study evaluated 96 New York Heart Association (NYHA) Class II-III patients ... [Published Reuters - 12 hours ago]
First reported Aug 30 2014 - Updated 23 hours ago - 2 reports

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

The magnitude of benefit with LCZ696 against enalapril in HF-REF patients was highly statistically significant and clinically important. In the study, the benefit of LCZ696 was seen early, was sustained and was consistent across subgroups. LCZ696:[1]Overall ... [Published InfoStor - Aug 30 2014]
First reported Aug 31 2014 - Updated Aug 31 2014 - 1 reports

Solid-TIMI 52 - Darapladib disappoints again – Anti-inflammatory treatment fails to prevent cardiac events

: A new phase III study evaluating the investigational agent darapladib in patients with an acute coronary syndrome (heart attack or unstable angina) has failed to show a reduction in major coronary events compared to placebo.Results of the double-blind, ... [Published European Society of Cardiology - Aug 31 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 4 reports

Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial

MARLBOROUGH, Mass.The study evaluated 96 New York Heart Association (NYHA) Class II-III patients with heart failure and an ejection fraction of less than 35%. All patients continued receiving optimal medical treatment for heart failure, but were randomized ... [Published Bio-Medicine - Aug 30 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Who Needs Zoledronic Acid in Early Breast Cancer?

Adjuvant Zoledronic Acid in Patients With Early Breast Cancer: Final Efficacy Analysis of the AZURE (BIG 01/04) Randomised Open-Label Phase 3 TrialColeman R, Cameron D, Dodwell D, et alLancet Oncol . 2014;15:997-1006Study SummaryThe AZURE trial was designed ... [Published General Medicine eJournal - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Amgen reports positive data from new cholesterol drug trial

:13 in Pharmaceutical Company Product News Amgen has announced results from a phase III trial that shows the benefits evolocumab can offer in treating patients with high cardiovascular risk and high cholesterol. The recent Japanese YUKAWA-2 study assessed ... [Published Zenopa - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Edison re-evaluates Onconova based on extended rigosertib timeline after trial failure

After failing to meet the primary endpoint of its trial of rigosertib (IV), oncology specialist Onconova (Nasdaq: ONTX) has informed the investment community that it will be pursuing an indication of the drug in patients where primary hypomethylating ... [Published Pharma Letter - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Baxter's Phase III hemophilia A trial meets primary endpoint

(MarketLine via COMTEX News Network) -- Baxter International Inc., a developer of new products for hemophilia and immune disorders, has announced that its Phase III pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant ... [Published PredictWallStreet - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

DEFINITIVE LE published: Directional atherectomy effective regardless of diabetes status

Patients with or without diabetes who underwent directional atherectomy for peripheral artery disease experienced similar rates of primary patency at 12 months, according to findings from the DEFINITIVE LE trial.The results, which were initially presented ... [Published Orthopedics Today - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Onyx's Phase III multiple myeloma trial fails to meet primary endpoint

Amgen, Inc., a biotechnology company, and its subsidiary, Onyx Pharmaceuticals, Inc., have announced that the Phase III clinical trial, FOCUS, did not meet its primary endpoint of improving overall survival, or OS, in patients with multiple myeloma. The ... [Published Individual.com - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 2 reports

Kindred study of canine pain drug misses endpoint

San Francisco-based Kindred Bioscience ($KIN) did not meet the primary endpoint during a trial of CereKin, its drug for canine osteoarthritis, based off studies for Amgen ($AMGN) and Pfizer's ($PFE) Enbrel. The study was randomized, double-blind and placebo-controlled ... [Published Fierce Biotech IT - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Eisai's Phase III lung cancer study fails to meet primary endpoint

Eisai Co., Ltd., a Japanese pharmaceutical company, has announced that the Phase III study, or Study 302, with its in-house developed anticancer agent, eribulin mesylate, in patients with advanced non-small cell lung cancer, or NSCLC, fails to meet primary ... [Published Individual.com - Aug 25 2014]

Quotes

Jan van de Winkel, CEO of Genmab said: "We continue to make solid progress across our business as the year progresses. The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed closely by approval in Europe for Arzerra in combination with chlorambucil or bendamustine. We were pleased to announce that the Phase III study of ofatumumab as maintenance therapy in relapsed CLL met its primary endpoint at an interim analysis. Furthermore, we announced three new Phase III studies of daratumumab in combination with backbone therapies, one in relapsed or refractory multiple myeloma and two in first line multiple myeloma. In July we reached a USD 25 million milestone based on progress in the first Phase III study under our collaboration with Janssen and have again been able to improve our financial guidance."
...represents one of the most important cardiology advances of the last decade," said  David Epstein , division head, Novartis Pharmaceuticals. "We want to thank leading cardiologists from around the world for their collaboration with us and their determination in advancing this important new life saving therapy for heart failure patients."
Professor Taborsky said: "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis (1) in people at mild to moderate risk of CVD. We found that moderate wine drinking was only protective in people who exercised. Red and white wine produced the same results."
Professor Taborsky said: "A rise in HDL cholesterol is the main indication of a protective effect against CVD, therefore we can conclude that neither red or white wine had any impact on study participants as a whole."

More Content

All (1166) | News (968) | Reports (0) | Blogs (170) | Audio/Video (0) | Fact Sheets (1) | Press Releases (16)
sort by: Date | Relevance
NECTAR-HF: Vagus nerve stimulation failed to im... [Published Orthopedics Today - 1 hour ago]
Genmab reports higher Q2 net loss, revises annu... [Published Individual.com - 2 hours ago]
ThromboGenics’ JETREA Receives Reimbursement in... [Published FirstWord Pharma - 3 hours ago]
UCB Says FDA Approves SNDA For VIMPAT [Published RTTNews.com - 3 hours ago]
Boehringer Ingelheim to present comprehensive d... [Published Scottrade - 4 hours ago]
Ultrathin, biodegradable stent proves noninferi... [Published Cardiology News - 5 hours ago]
CONFIRM-HF study demonstrates that Ferinject® i... [Published Noodls - 5 hours ago]
Boston Scientific Corporation announces primary... [Published Reuters - 12 hours ago]
Ivabradine makes no dent on mortality in patent... [Published Cardiovascular Business - 14 hours ago]
New Novartis Heart Failure Medicine could be Gr... [Published PharmaAsia - 18 hours ago]
Trial Provokes Sound And Fury Over Controversia... [Published Forbes.com - 20 hours ago]
Novartis' investigational heart failure drug LC... [Published Pharma Letter - 20 hours ago]
Large-scale Study Confirms Growing Body of Clin... [Published Investor's Business Daily - 21 hours ago]
Novartis' LCZ696 cuts cardiovascular deaths by ... [Published FirstWord Pharma - 21 hours ago]
LISTEN - Statin standoff: Does rosuvastatin tip... [Published European Society of Cardiology - Aug 31 2014]
Solid-TIMI 52 - Darapladib disappoints again – ... [Published European Society of Cardiology - Aug 31 2014]
Novel transcatheter valve shows promise in real... [Published Orthopedics Today - Aug 31 2014]
Wine only protects against CVD in people who ex... [Published Bio-Medicine - Aug 31 2014]
Large-scale Study Confirms Growing Body of Clin... [Published Wall Street Business Network - Aug 31 2014]
Sanofi, Regeneron Report Positive Results From ... [Published RTTNews.com - Aug 31 2014]
Wine only protects against CVD in people who ex... [Published EurekAlert! - Aug 31 2014]
Retrievable transcatheter aortic valve effectiv... [Published Bio-Medicine - Aug 31 2014]
Retrievable transcatheter aortic valve effectiv... [Published EurekAlert! - Aug 31 2014]
Novartis’ New Heart Failure Drug Cuts Cardiovas... [Published International Business Times - Aug 30 2014]
Boston Scientific Announces Primary Endpoint Re... [Published Bio-Medicine - Aug 30 2014]
Boston Scientific Announces Primary Endpoint Re... [Published Minyanville - Aug 30 2014]
Boston Scientific Announces Primary Endpoint Re... [Published ADVFN UK - Aug 30 2014]
Boston Scientific Announces Primary Endpoint Re... [Published PR Newswire: Health - Aug 30 2014]
Novartis' investigational heart failure medicin... [Published BusinessWeek - Aug 30 2014]
Intravenous iron supplement can improve quality... [Published News-Medical.Net - Aug 30 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Boston Scientific Announces Primary Endpoint Re... [Published PR Newswire: Health - Aug 30 2014]
MARLBOROUGH, Mass., Aug. 30, 2014 /PRNewswire/ -- Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating ...
OncoPep nabs $6.9 mln Series B [Published PE Hub Blog - Aug 29 2014]
OncoPep has received $6.9 million in Series B funding. The investors included The Leukemia & Lymphoma Society . OncoPep is focused on preventing the progression of cancer. PRESS RELEASE BOSTON — OncoPep, Inc., today announced the closing of $6.9 ...
Baxter reports positive top-line results from P... [Published PBR - News - Aug 25 2014]
Nektar Therapeutics reports Baxter International has announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic ...
BioNews [8.18.14] [Published eClinical Trends - Aug 18 2014]
Top News HeadlineCompanyType Pfizer Announces Submission of Palbociclib New Drug Application to the FDA PfizerNDA for palbociclib Novo Nordisk accepts a $90K slap on the hand for delaying news of Tresiba setback Novo NordiskAccepts fine ...
BioNews [8.15.14] [Published eClinical Trends - Aug 15 2014]
Top News HeadlineCompanyType Gilead fends off Roche as hep C heavyweights fight for blockbuster rights GileadHep C Drug Chikungunya vaccine shows antibody response in Phase I trial NIAIDPositive results CF biotech ProQR shoots for a ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
NeuroSearch appeals Copenhagen City Court judgm... [Published GlobeNewswire: Acquisitions News - Aug 18 2014]
Sanofi and Regeneron Announce Positive Results ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
GSK and Genmab announce top-line results from a... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Lundbeck provides update on the development pro... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
DGAP-News: PAION REPORTS POSITIVE PHASE II RESU... [Published GlobeNewswire: Advertising News - May 28 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.